A sustainable amperometric biosensor for the analysis of ascorbic, benzoic, gallic and kojic acids through catechol detection. Innovation and signal processing.

In this work, we present a new catechol amperometric biosensor fabricated on the basis of naturally available enzymes in common mushrooms. The biosensor response mechanism comprises the reduction of the quinone exclusively produced in the oxidation of the catechol present in the sample, which is catalyzed by tyrosinase enzyme. The new catechol biosensor has demonstrated excellent analytical performance at increasing catechol concentrations in the sample solution, which includes superior reproducibility for several electrodes and long-term stability.

[Aetiology and diagnosis of community acquired pneumonia and its complicated forms].

Community Acquired Pneumonia (CAP) is a common childhood disease, involving several paediatric subspecialties in its diagnosis and treatment. This has prompted the Spanish Society of Paediatric Pulmonology (SENP) and the Spanish Society of Paediatric Infectious Diseases (SEIP) to prepare a consensus document on the diagnosis of CAP, assessing the practical aspects by means of evidence-based medicine. It discusses the aetiology and epidemiology, with the current changes and the validity of certain laboratory tests, such as acute phase reactants, microbiological and imaging techniques, guiding the paediatricians in the real value of these tests.

Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease.

Introduction: Rivastigmine transdermal patches for the treatment of Alzheimer's disease (AD) have potential benefits compared to capsules because of their sustained absorption through the skin, good local tolerability and reduction of gastrointestinal problems.

Purpose: To assess gastrointestinal and skin tolerability and the need for optimal dose titration of rivastigmine transdermal patches in Alzheimer's disease patients previously treated with oral rivastigmine.

Patients And Methods: A multicenter, randomized, open-label study including patients with mild to moderate AD (DSM-IV) previously treated with rivastigmine capsules (6-12 mg/day) was conducted.